The robust Anti-VEGF Market growth is directly attributable to the escalating prevalence of chronic conditions that involve pathological angiogenesis. The primary driver in the ophthalmic segment is the dramatic increase in wet Age-related Macular Degeneration (AMD) and Diabetic Macular Edema (DME) cases, linked directly to the aging global demographic and the diabetes pandemic. As lifespans lengthen and lifestyle diseases become more common, the patient pool requiring long-term anti-VEGF therapy expands continuously. Improved diagnostic tools, such as Optical Coherence Tomography (OCT), also contribute by enabling earlier and more precise identification of treatable disease, thus pulling more patients into the treatment funnel.

Beyond ophthalmology, the stable use of anti-VEGF agents in various oncology settings provides a resilient foundation for overall market growth. The demonstrated clinical benefit across multiple cancer types, often in combination with chemotherapy or immunotherapy, ensures a steady demand. Furthermore, research into novel anti-VEGF formulations, including small molecule inhibitors and gene therapies aimed at long-term VEGF suppression, promises to sustain innovation and extend the market's growth trajectory. The commitment by global health systems to prevent vision loss, recognizing the substantial socio-economic cost of blindness, solidifies the financial support and reimbursement for these highly effective, yet expensive, therapeutic agents.